<Anchor>



There has been a controversy that the AstraZeneca vaccine, which is being produced on commission by Korea, is less effective in the elderly.

In the meantime, Germany recommended that only people under the age of 65 get the AstraZeneca vaccine, saying that it did not have sufficient clinical trials.



Reporter Jeon Hyeong-woo on the report.



<Reporter>



German media reports that the German Immunization Commission recommended that the AstraZeneca vaccine be administered only to people aged 18 to 64 years old.



This is because sufficient clinical trials have not been conducted for the age group over 65.



[Jens Sfan/German Health Minister: AstraZeneca has little data from a study of older people.

Not bad data, but small.]



In this regard, the European Medicines Agency is said to be deciding whether to approve conditional marketing of the AstraZeneca vaccine sooner or later.



There is also a growing controversy over the disruption in the supply of AstraZeneca vaccines.



"If a solution is not available, all options and legal responses will be considered," said Charles Michel, executive chairman of the European Union Summit.



Earlier over the weekend, AstraZeneca informed the EU that it could only deliver 30 million batches out of the 80 million batches it had decided to supply in the first quarter due to production disruption, and the EU rejected it as a violation of the contract and could not accept it.



[Stella Kyriachides/EU Health Commissioner: Pharmaceutical companies and vaccine developers have moral, social, and contractual responsibilities to adhere to.]



Reuters reported that if the EU does not fulfill its promise to supply vaccines to pharmaceutical companies in Europe It is reported that it will introduce a system to block the export of vaccines produced in allied member states.